Blog

Product characterisation key to successful CAR T therapies, Autolus – BioPharma-Reporter.com


BioPharma-Reporter.com

Product characterisation key to successful CAR T therapies, Autolus
BioPharma-Reporter.com
And speaking at last month's Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam, Jim Faulkner, SVP and head of manufacturing at UK-based CAR T-cell therapy developer Autolus, said it was imperative to reduce the costs to allow such

2018-01-16 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.